scholarly journals The significance of simultaneous measurement of serum thyroglobulin and thyroglobulin antibody during the follow up of patients with differentiated thyroid carcinoma

2011 ◽  
Vol 152 (19) ◽  
pp. 743-752
Author(s):  
Zoltán Lőcsei ◽  
Dóra Horváth ◽  
Károly Rácz ◽  
Erzsébet Toldy
Keyword(s):  
Thyroid Carcinoma ◽  
Antibody Level ◽  
Differentiated Thyroid Carcinoma ◽  
Review Literature ◽  
Antibody Concentration ◽  
Serum Samples ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Antibody ◽  
Current Guidelines

Serum thyroglobulin is an essential marker during the follow-up of patients with differentiated thyroid carcinoma. Demonstration of the total absence of thyroglobulin is not possible by immunoanalytic methods if thyroglobulin antibody is present in serum samples that occur in almost 20% of patients with differentiated thyroid carcinoma. Therefore, current guidelines recommend estimation of thyroglobulin levels only if quantitative level of thyroglobulin antibody is known. However, normal thyroglobulin antibody level fails to exclude interference with the antibody, because antibody concentration within the normal range may interfere with the thyroglobulin assay. In this respect recommendations are not consistent because they distinguish only occasionally cases with normal and those with non-detectable serum thyroglobulin level. In addition, the possible impact of normal thyroglobulin antibody level on the thyroglobulin assay has not been entirely explored. Authors review literature data and current guidelines on the analytical and preanalytical limitations of the thyroglobulin and thyroglobulin antibody measurements. On the basis of their own studies, authors make recommendation for improvement of the diagnostic accuracy of the thyroglobulin measurement. Orv. Hetil., 2011, 152, 743–752.

Serum Thyroglobulin Determinations in Patients with Differentiated Thyroid Carcinoma

1983 ◽  
Vol 22 (04) ◽  
pp. 204-211 ◽  
Author(s):  
J. Němec ◽  
V. Zamrazil ◽  
S. Váňa ◽  
D. Pohunková ◽  
S. Rohling ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Healthy Subjects ◽  
Distant Metastases ◽  
Diagnostic Value ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Antibody ◽  
Long Term Follow Up

Serum thyroglobulin levels were measured in 636 patients with differentiated thyroid carcinoma, in whom altogether 1240 determinations were performed in different phases of disease and treatment. A modified sensitive radioimmunoassay was employed using an own high-specific thyroglobulin antibody. The results showed that both the majority of patients with functioning metastases accumulating radioiodine and with non-functioning metastases which could not be detected by scanning had higher serum TG levels, compared with a group of healthy subjects. However, “normal” TG values in patients with metastases, especially non-functioning, were found too. Thus, these findings decrease the diagnostic value of the TG determination. The highest TG values were found in patients with distant metastases of differentiated thyroid carcinoma (in lungs and bones); on the other hand, the proportion of patients with lymph-node(s) métastasés and “normal” TG levels was relatively high. We suggest that the serum TG determination cannot generally replace scanning with l31I and cannot serve as the only test, while being a helpful indicator in the long-term follow-up of differentiated thyroid cancer patients.

131J-speichernde pulmonale und ossäre Metastasen differenzierter Schilddrüsenkarzinome bei niedrigem Serum-Thyreoglobulinspiegel – Ausnahme in der Tumornachsorge?

1987 ◽  
Vol 26 (03) ◽  
pp. 139-142 ◽  
Author(s):  
G. Arning ◽  
O. Schober ◽  
H. Hundeshagen ◽  
Ch. Ehrenheim
Keyword(s):  
Serum Level ◽  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Level ◽  
Low Serum

In the follow-up of differentiated thyroid carcinoma it is discussed whether the tumormarker thyroglobulin can replace the1311 scan, especially when the thyroglobulin serum level is normal. A positive1311 scan of metastases in the follow-up of patients with differentiated thyroid carcinoma combined with a low serum thyroglobulin level is extremely rare. The literature shows a frequency of about 4%. Recently we found 3 cases with a positive1311 scan demonstrating pulmonary and bone metastases whereas the serum thyroglobulin level was low.

The usefulness of serum thyroglobulin in the follow-up of differentiated thyroid carcinoma in children

1992 ◽  
Vol 20 (3) ◽  
pp. 201-208 ◽  
Author(s):  
Jeremy M. W. Kirk ◽  
Catherine Mort ◽  
David B. Grant ◽  
Richard J. Touzel ◽  
Nicholas Plowman
Keyword(s):  
Thyroid Carcinoma ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin

scholarly journals Clinical Utility of an Automated Immunochemiluminometric Thyroglobulin Assay in Differentiated Thyroid Carcinoma

2006 ◽  
Vol 52 (4) ◽  
pp. 686-691 ◽  
Author(s):  
Adrienne CM Persoon ◽  
Johannes MW Van Den Ouweland ◽  
Juergen Wilde ◽  
Ido P Kema ◽  
Bruce HR Wolffenbuttel ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Detection Limit ◽  
Thyroid Carcinoma ◽  
Clinical Utility ◽  
Clinical Performance ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Samples ◽  
New Concepts ◽  
Measurable Serum

Abstract Background: Thyroglobulin (Tg) measurements are important in the follow-up of patients with differentiated thyroid carcinoma (DTC). We evaluated the analytical and clinical performance of a new automated immunochemiluminometric assay for Tg (Tg-ICMA; Nichols Advantage Tg; Nichols Institute Diagnostics). Methods: We used the Tg-ICMA to measure Tg concentrations in serum samples from 110 Tg antibody–negative DTC patients undergoing thyroid-hormone suppression therapy. Disease state at the time of measurement was assessed on the basis of routine follow-up data. We compared the clinical performance of this assay with the routinely used IRMA (ELSA-hTG; CIS Bio International). Results: The detection limit and functional sensitivity of the Tg-ICMA, based on direct calibration to CRM-457, were 0.05 and 0.6 μg/L, respectively. No Tg-IRMA-positive cases were missed by the Tg-ICMA. Tg was measurable by Tg-ICMA (0.6–8.6 μg/L) but undetectable by Tg-IRMA (<1.5 μg/L) in 12 patients (11%). Clinical data showed evidence of disease in 4 of 12 patients (33%). Conclusions: The Tg-ICMA is a sensitive and reproducible assay for identifying patients in follow-up for DTC with evidence of disease, but uncertainty remains with regard to interpreting findings of measurable serum Tg in patients with no evidence of disease. Follow-up data are required to determine the predictive value of these isolated Tg results. New concepts, i.e., serial Tg measurements and risk stratification of patients, need to be tested to confirm the applicability of this assay for clinical practice.

How to deal with undetectable and low measurable serum thyroglobulin levels in the follow-up of patients with differentiated thyroid carcinoma?

1985 ◽  
Vol 110 (4) ◽  
pp. 487-492 ◽  
Author(s):  
Matti Välimäki ◽  
Bror-Axel Lamberg
Keyword(s):  
Thyroid Carcinoma ◽  
Neck Region ◽  
Differentiated Thyroid Carcinoma ◽  
Whole Body ◽  
Cancer Tissue ◽  
Serum Thyroglobulin ◽  
Before And After ◽  
Measurable Serum

Abstract. Serum thyroglobulin (Tg) was measured in 52 patients 3 months to 15 years (mean 5.3 years) after thyroidectomy with or without subsequent radioablation for differentiated thyroid carcinoma, before and after the interruption of suppressive thyroxine (T4) replacement therapy for 5 weeks. Whole body scintigraphy was carried out at the end of the T4 withdrawal period. Serum Tg was undetectable (< 3 μg/l) in 38 patients on T4 therapy, in 18 the scintigraphy showed a minimal accumulation in the neck region and in 20 no uptake anywhere after withdrawal of T4. In the former group Tg rose in 10 patients to 4–21 μg/l when off T4 which seemed to correspond to the normal tissue left in situ, in the latter group Tg rose only in 2 patients to 5 and 21 μg/l, respectively. Two patients out of 14 with detectable Tg on T4 had pulmonary metastases as uncovered by whole body scintigraphy (in one of them Tg rose from 12 μg/l on T4 to 1200 μg/l off T4) and 6 patients were suspected for having recidual cancer tissue (2 patients had a negative scintigraphy) because the Tg rose (66– 215 μg/l) over the upper limit of the reference range (< 50 μg/l) after T4 withdrawal. In conclusion, in the follow-up of patients with differentiated thyroid carcinoma no routine scans are needed as long as serum Tg remains undetectable but further examinations are shortly warranted when detectable Tg is obtained during T4 suppression.

Rising serum thyroglobulin in the follow-up of patients with differentiated thyroid carcinoma: the role of FDG PET-CT

2014 ◽  
Author(s):  
Paulina Godlewska ◽  
Elzbieta Bruszewska ◽  
Grazyna Lapinska ◽  
Agnieszka Fijolek-Warszewska ◽  
Marek Dedecjus
Keyword(s):  
Thyroid Carcinoma ◽  
Fdg Pet ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Pet Ct ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document